Bright Minds Biosciences Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DRUG.CN research report →
Price Chart
About the company
Bright Minds Biosciences Inc. , a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
- CEO
- Ian McDonald
- IPO
- 2021
- Employees
- 26
- HQ
- New York, NY, US
Get TickerSpark's AI analysis on DRUG.CN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.07B
- P/E
- -37.73
- PEG
- 0.51
- P/S
- 0.00
- P/B
- 3.49
- EV/EBITDA
- -19.19
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -12.56%
- ROIC
- -12.92%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-76,868-4.8%
- Op Income
- $-13,937,584
- Net Income
- $-12,229,348-336.5%
- EPS
- $-1.78-173.8%
- OCF Growth
- -369.8%
- FCF Growth
- -369.8%
- 52W High
- $170.00
- 52W Low
- $53.99
- 50D MA
- $100.64
- 200D MA
- $106.72
- Beta
- 0.09
- RSI (14)
- 52
- Avg Volume
- 796
No earnings-call transcripts are available for DRUG.CN yet.
- Free Float
- 62.4%
- Shares Outstanding
- 9.79M
- Float Shares
- 6.11M
Held by 43 ETFs
Biggest fund positions in DRUG.CN by dollar value.
Our DRUG.CN coverage
Recent articles, reports, and earnings notes.
No research on DRUG.CN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DRUG.CN report →Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.